Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer

This study was an open, single center, prospective cohort study design. Subjects with advanced gastric cancer who had received first-line chemotherapy (cohort 1) and systematic chemotherapy combined with immunotherapy (cohort 2) were included in this study. 20 cases were included in each population, and a total of 40 subjects were planned to be included.

Trial Details

NCT ID
NCT07320586
Phase
PHASE2
Sponsor
Shandong Tumor Hospital
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • Camrelizumab
  • Nab paclitaxel
Locations (sample)
  • Jinan, Shandong, China|36.66833,116.99722

Key Eligibility Criteria

  • Age range: 18 to 75 years old, both male and female are acceptable;
  • Patients with gastric adenocarcinoma or gastroesophageal junction adenocarcinoma diagnosed by histology or cytology;
  • Gastric cancer patients who have previously received first-line systemic chemotherapy (queue 1) or systemic chemotherapy combined with immunotherap…
  • According to the evaluation criteria for solid tumor efficacy 1.1 (RECIST v1.1), there should be at least one measurable lesion that has not receiv…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →